COMPOSITION
Each VIRUSTAT tablet contains: Active ingredient: Acyclovir 200, 400 or 800 mg.
Each 5 ml suspension contains: Acyclovir 200 mg. For more information Click here to read the Virustat Patient Information Leaflet.
THERAPEUTIC INDICATIONS
Herpes Zoster Infections: VIRUSTAT is indicated for the acute treatment of herpes zoster (shingles).
Genital Herpes: VIRUSTAT is indicated for the treatment of initial episodes and management of recurrent episodes of genital herpes.
Chickenpox: VIRUSTAT is indicated for the treatment of chickenpox (varicella). For more information Click here to read the Virustat Patient Information Leaflet.
ADVERSE REACTIONS
General: Anaphylaxis, angioedema, fever, headache, pain, peripheral edema.
Nervous: Aggressive behavior, agitation, ataxia, coma, confusion, decreased conscious-ness, delirium, dizziness, dysarthria, encephalopathy, hallucinations, paresthesia, psychosis, seizure, somnolence, tremors. These symptoms may be marked, particularly in older adults or in patients with renal impairment.
Digestive: Diarrhea, gastrointestinal distress, nauseaز
Hematologic and Lymphatic: Anemia, leukocytoclastic vasculitis, leukopenia, lymphad-enopathy, thrombocytopenia .
Hepatobiliary Tract and Pancreas: Elevated liver function tests, hepatitis, hyperbilirubine-mia, jaundice.
Musculoskeletal: Myalgia.
Skin: Alopecia, erythema multiforme, photosensitive rash, pruritus, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria.
Special Senses: Visual abnormalities.
Urogenital: Renal failure, renal pain (may be associated with renal failure), elevated blood urea nitrogen, elevated creatinine, hematuria. For more information Click here to read the Virustat Patient Information Leaflet.
Dosage In adults
Treatment of Herpes simplex:-For treatment of Herpes simplex infections, 200 mg VIRUSTAT should be taken five: times daily at approximately four-hourly intervals omitting the night time dose. Treatment should continue for five days but in severe initial infections it may have to be extended.
In severely immune-compromised patients (e.g. after marrow transplant) or in patients with impaired absorption from the gut the dose can be doubled to 400 mg.
Dosing should begin as early as possible after the start of an infection; for recurrent episodes this should preferably be during the prodromal period or when lesions first appear. For more information Click here to read the Virustat Patient Information Leaflet.
PHARAONIA PHARMACEUTICALS (PHARO PHARM)
Patient Information Leaflet
Virustat Arabic content
فيروستات نشرة معلومات المريض
